January 3rd 2024
Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.
December 27th 2023
Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.
Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
December 20th 2023
Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.
Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.
December 13th 2023
Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.
Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.
December 6th 2023
Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.
The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.
November 29th 2023
Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.
Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.
November 17th 2023
Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.
Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.
November 5th 2021
Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.
May 27th 2014
Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.